Beigene Ltd ADR (BGNE)

Weibo Corp (WB), on Wednesday, joined previously identified Chinese stocks that may be delisted from U.S. exchanges. More could follow and Alibaba (BABA) could be in SEC crosshairs too.

Which Chinese Stocks Could Get Delisted? 6 Companies to Watch.

By Chris MacDonald, InvestorPlace Contributor Mar 25, 2022

Today, news that Weibo has been added to the SEC's list of at-risk companies for delisting has investors selling Chinese stocks in a big way.

Chinese Stock Delisting News: Why Are BABA, DIDI, IQ, YUMC, ACMR, BGNE and ZLAB Down Today?

By William White, InvestorPlace Writer Mar 11, 2022

Chinese stock delisting news today has several big names in the country seeing their shares slip on fears they could be next.

BAD ETF: The Top “Sin Stock” Holdings in the New Anti-ESG Fund That Debuts Today

By William White, InvestorPlace Writer Dec 22, 2021

There's a new ETF on the block from BAD Investment Company and it seeks to offer investments in sin stocks for interested traders.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

By William White, InvestorPlace Writer Dec 15, 2021

We're at the halfway point of the week but there's no slowing down as we dive into the biggest pre-market stock movers for Wednesday!

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

By William White, InvestorPlace Writer Sep 17, 2021

There's only one day of trading left so let's start it off right with a look at the biggest pre-market stock movers for Friday.

FDA accepts BeiGene license application for gastric cancer combo therapy (NASDAQ:BGNE)

From Seeking Alpha Feb 27, 2024

BeiGene's biologics license application for Tevimbra, a combination therapy for gastric cancer, has been accepted by the FDA, with a target action date set...

BeiGene gets EU backing for lung cancer therapy (NASDAQ:BGNE)

From Seeking Alpha Feb 26, 2024

BeiGene receives positive CHMP opinion for tislelizumab, an anti-PD-1 treatment for non-small cell lung cancer, expanding its potential indications.

BeiGene GAAP EPS of -$3.53 beats by $0.38, revenue of $634.4M misses by $1.75M (NASDAQ:BGNE)

From Seeking Alpha Feb 26, 2024

BeiGene reported fourth-quarter and full-year 2023 financial results, with a GAAP EPS of -$3.53, beating estimates by $0.38.

5 Biotech Stocks That Could Be Big Winners in 2024 and Beyond

From The Motley Fool Jan 15, 2024

These five biotech companies could have a lot of room to run.

BeiGene's multiple myeloma drug gets orphan drug status (NASDAQ:BGNE)

From Seeking Alpha Nov 21, 2023

The U.S. FDA grants orphan drug designation to BeiGene's sonrotoclax for relapsed/refractory multiple myeloma treatment.

Why BeiGene Stock Jumped Thursday

From The Motley Fool Apr 6, 2023

A collaboration deal helped send the Chinese biotech stock higher.

Beigene Ltd ADR (BGNE)

BGNE Stock Earnings: BeiGene Beats EPS, Beats Revenue for Q1 2024

Get Rich Quick With These 3 Biotech Stocks to Buy Now

7 Biotech Stocks to Buy for Big-Time Gains

7 Biotech Stocks That Could Cure Your Portfolio Woes

Top 5 Stocks for 2024

Louis Navellier's Total Grade

Is ? a BUY?

Louis Navellier's Total Grade

Louis Navellier's Total Grade

Fundamental Grade

Quantitative Grade

Beigene Ltd ADR (BGNE)

Top 5 Stocks for 2024

Louis Navellier's Total Grade

Is ? a BUY?

Louis Navellier's Total Grade

Louis Navellier's Total Grade

Fundamental Grade

Quantitative Grade

BGNE Stock Predictions, Articles, and Beigene Ltd ADR News

Subscriber Sign in